Press Releases McKesson Corporation

Equities

MCK

US58155Q1031

Market Closed - Nyse Other stock markets 04:00:02 2024-05-03 pm EDT			5-day change	1st Jan Change
528.9 ^USD	-0.27%		-2.66%	+14.23%

Apr. 30	Citigroup Adjusts Price Target on McKesson to $620 From $575	MT
Apr. 24	McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

McKesson : OJEMDA FDA Approved for Pediatric Low Grade Glioma	Apr. 26	PU
McKesson : Ontada Names Jade Cusick Chief Commercial Officer	Apr. 25	PU
McKesson Corporation Declares Quarterly Dividend	Apr. 24	BU
McKesson Launches Project Oasis to Address Pharmacy Deserts in Underserved Communities	Apr. 03	AQ
Significant Implications For FCA Defendants: Second Circuit Clarifies "Willfulness" In McKesson Decision	Apr. 03	AQ
"Willfulness" As "Knowledge Of Illegality": Second Circuit Adopts Prevailing Federal AKS Scienter Interpretation While Reviving State FCA Claims Over Potentially Different State AKS Scienter Standards	Apr. 02	AQ
McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date	Mar. 27	BU
McKesson Invites Community Pharmacists to Push the Industry Forward, Together	Mar. 15	AQ
McKesson : Barclays Global Healthcare Conference Transcript	Mar. 14	PU
Thinking about trading options or stock in NVIDIA, Arm Holdings, Cisco Systems, McKesson, or Roku?	Feb. 20	PR
McKesson: Fiscal Q3 Earnings Snapshot	Feb. 07	AQ
McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance	Feb. 07	BU
McKesson Corporation Declares Quarterly Dividend	Feb. 01	BU
McKesson to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 09	BU
Treble Damages Require Willful, Knowing Conduct, Ninth Circuit Says	Jan. 03	AQ
McKesson Corporation Announces Third Quarter Fiscal 2024 Earnings Release Date and Participation in January Conference	Dec. 27	BU
McKesson : FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson	Dec. 20	PU
McKesson : OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson	Dec. 05	PU
TRUQAP, FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson	Dec. 04	AQ
McKesson : TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson	Dec. 01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases McKesson Corporation

Equities

MCK

US58155Q1031

Press Releases

Filters